Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

• US 20050119310A1
• Filed: 02/13/2001
• Published: 06/02/2005
• Est. Priority Date: 02/14/2000
• Status: Abandoned Application

• Current Assignee: Pharmacia Corporation (Pfizer Inc.)
• Original Assignee: Pharmacia Corporation (Pfizer Inc.)
• Inventors: Bryant, Kimberly, Mueller, Richard A., Bryant, Martin L.
• Application Number:
  US10/203,769
• Publication Number:
  US 20050119310A1
• Time in Patent Office: Days
• US Class Current: 514/328
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/20 for DNA viruses

Abstract

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Claims

1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

2. The method of claim 1, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

3. The method of claim 2, wherein R is nonyl.

4. The method of claim 1, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

5. The method of claim 4, wherein R is nonyl.

6. The method of claim 5, wherein said alkanoyl is butanoyl.

7. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

8. The method of claim 1, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

9. A method as set forth in claim 1 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

10. A method as set forth in claim 1 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

11. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral composition comprising an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

12. The method of claim 11, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

13. The method of claim 12, wherein R is nonyl.

14. The method of claim 11, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

15. The method of claim 14, wherein R is nonyl.

16. The method of claim 15, wherein said alkanoyl is butanoyl.

17. The method of claim 11, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

18. The method of claim 11, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

19. A method as set forth in claim 11 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

20. A method as set forth in claim 11 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

21. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral composition consisting essentially of an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

22. The method of claim 21, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

23. The method of claim 22, wherein R is nonyl.

24. The method of claim 21, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

25. The method of claim 24, wherein R is nonyl.

26. The method of claim 25, wherein said alkanoyl is butanoyl.

27. The method of claim 21, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

28. The method of claim 21, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsul fate, ethanesulfonate, glucoheptano ate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

29. A method as set forth in claim 21 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

30. A method as set forth in claim 21 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

31. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

32. The method of claim 31, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

33. The method of claim 32, wherein R is nonyl.

34. The method of claim 31, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

35. The method of claim 34, wherein R is nonyl.

36. The method of claim 35, wherein said alkanoyl is butanoyl.

37. The method of claim 31, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

38. The method of claim 31, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

39. A method as set forth in claim 31 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

40. A method as set forth in claim 31 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

41. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal an antiviral effective amount of an antiviral compound consisting essentially of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

42. The method of claim 41, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

43. The method of claim 42, wherein R is nonyl.

44. The method of claim 41, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

45. The method of claim 44, wherein R is nonyl.

46. The method of claim 45, wherein said alkanoyl is butanoyl.

47. The method of claim 41, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

48. The method of claim 41, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsul fate, ethanesulfonate, glucoheptano ate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

49. A method as set forth in claim 41 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

50. A method as set forth in claim 41 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

51. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal a first amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof:

52. The method of claim 51, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

53. The method of claim 52, wherein R^A is nonyl.

54. The method of claim 51, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

55. The method of claim 54, wherein R^A is nonyl.

56. The method of claim 55, wherein said alkanoyl is butanoyl.

57. The method of claim 51, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

58. The method of claim 51, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;

(−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC);

(−

)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);

(−

)2′

,3′

, dideoxy-3′

-thiacytidine [(−

)-SddC];

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-dexocytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-cytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-cytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-cytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluorothymidine (FddThd);

2′

,3′

-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2′

,3′

-dideoxy-beta-L-5-thiacytidine;

2′

,3′

-dideoxy-beta-L-5-cytidine (beta-L-ddC);

9-(1,3-dihydroxy-2-propoxymethyl)guanine;

2′

-deoxy-3′

-thia-5-florocytosine;

3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one (gancyclovir);

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);

3′

-azido-3′

-deoxythymidine (AZT);

3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

9-(2-phosphonyl-methoxyethyl)-2′

,6′

-diaminopurine-2′

,3′

-dideoxyriboside;

9-(2-phosphonylmethoxyethyl)adenine (PMEA);

acyclovir triphosphate (ACVTP);

D-carbocyclic-2′

-deoxyguanosine (CdG);

dideoxy-cytidine;

dideoxy-cytosine (ddC);

dideoxy-guanine (ddG);

dideoxy-inosine (ddI);

E-5-(2-bromovinyl)-2′

-deoxyuridine triphosphate;

fluoro-arabinofuranosyl-iodouracil;

1-(2′

-deoxy-2′

-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);

stavudine;

9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5′

-monophosphate monohydrate (Ara-AMP);

2-deoxy-3′

-thia-5-fluorocytidine;

2′

,3′

-dideoxy-guanine; and

2′

,3′

-dideoxy-guanosine.

59. A method as set forth in claim 51 wherein R^A is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀ and branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain.

60. A method as set forth in claim 51 wherein R^A is selected from the group consisting of alkoxyalkyl, arylalkyl, and cycloalkylalkyl.

61. The method of claim 59, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof;

and

wherein said nucleoside or nucleotide antiviral compound is (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC).

62. A method as set forth in claim 51 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof.

63. A method as set forth in claim 51 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof

64. A method for treating a hepatitis B virus infection in a mammal, comprising administering to said mammal from about 0.1 mg/kg/day to about 100 mg/kg/day of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof:

65. The method of claim 64, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

66. The method of claim 65, wherein R^A is nonyl.

67. The method of claim 64, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

68. The method of claim 67, wherein R^A is nonyl.

69. The method of claim 68, wherein said alkanoyl is butanoyl.

70. A method as set forth in claim 64 wherein R^A is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀ and branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain.

71. A method as set forth in claim 64 wherein R^A is selected from the group consisting of alkoxyalkyl, arylalkyl, and cycloalkylalkyl.

72. The method of claim 64, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

73. The method of claim 64, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;

(−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC);

(−

)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);

(−

)2′

,3′

, dideoxy-3′

-thiacytidine [(−

)-SddC];

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribo furanosyl-1,2,4-triazole-3-carboxamide;

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-dexocytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-cytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-cytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-cytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluorothymidine (FddThd);

2′

,3′

-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2′

,3′

-dideoxy-beta-L-5-thiacytidine;

2′

,3′

-dideoxy-beta-L-5-cytidine (beta-L-ddC);

9-(1,3-dihydroxy-2-propoxymethyl)guanine;

2′

-deoxy-3′

-thia-5-fluorocytosine;

3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one (gancyclovir);

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);

3′

-azido-3′

-deoxythymidine (AZT);

3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

9-(2-phosphonyl-methoxyethyl)-2′

,6′

-diaminopurine-2′

,3′

-dideoxyriboside;

9-(2-phosphonylmethoxyethyl)adenine (PMEA);

acyclovir triphosphate (ACVTP);

D-carbocyclic-2′

-deoxyguanosine (CdG);

dideoxy-cytidine;

dideoxy-cytosine (ddC);

dideoxy-guanine (ddG);

dideoxy-inosine (ddI);

E-5-(2-bromovinyl)-2′

-deoxyuridine triphosphate;

fluoro-arabinofuranosyl-iodouracil;

1-(2′

-deoxy-2′

-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);

stavudine;

9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5′

-monophosphate monohydrate (Ara-AMP);

2-deoxy-3′

-thia-5-fluorocytidine;

2′

,3′

-dideoxy-guanine; and

2′

,3′

-dideoxy-guanosine.

74. The method of claim 64, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof;

and

wherein said nucleoside or nucleotide antiviral compound is (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC).

75. A method as set forth in claim 64 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

76. A method as set forth in claim 64 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

77. A method for treating a hepatitis B virus infection in a human patient, comprising administering to said human patient from about 0.1 mg/kg/day to about 100 mg/kg/day of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound selected from the group consisting N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof, and from about 0.1 mg/person/day to about 500 mg/person/day of (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate.

78. A method as set forth in claim 77 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

79. A method as set forth in claim 77 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

80. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

81. The method of claim 80, further comprising administering said at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

82. The method of claim 80, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

83. The method of claim 82, wherein R is nonyl.

84. The method of claim 80, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

85. The method of claim 84, wherein R is nonyl.

86. The method of claim 85, wherein said alkanoyl is butanoyl.

87. The method of claim 80, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

88. The method of claim 80, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

89. A method as set forth in claim 80 comprising treating a hepatitis B virus infection comprising administering to said mammal an anti-hepatitis B virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof.

90. A method as set forth in claim 80 comprising treating a hepatitis C virus infection comprising administering to said mammal an anti-hepatitis C virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof

91. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

92. The method of claim 91, further comprising administering said at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

93. The method of claim 91, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

94. The method of claim 93, wherein R is nonyl.

95. The method of claim 91, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

96. The method of claim 95, wherein R is nonyl.

97. The method of claim 96, wherein said alkanoyl is butanoyl.

98. The method of claim 91, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

99. The method of claim 91, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

100. A pharmaceutical composition, comprising an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

101. The pharmaceutical composition of claim 100, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

102. The pharmaceutical composition of claim 101, wherein R is nonyl.

103. The pharmaceutical composition of claim 100, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

104. The pharmaceutical composition of claim 103, wherein R is nonyl.

105. The pharmaceutical composition of claim 104, wherein said alkanoyl is butanoyl.

106. The pharmaceutical composition of claim 100, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

107. The pharmaceutical composition of claim 100, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

108. A pharmaceutical composition, consisting essentially of an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

109. The pharmaceutical composition of claim 108, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

110. The pharmaceutical composition of claim 109, wherein R is nonyl.

111. The pharmaceutical composition of claim 108, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

112. The pharmaceutical composition of claim 111, wherein R is nonyl.

113. The pharmaceutical composition of claim 112, wherein said alkanoyl is butanoyl.

114. The pharmaceutical composition of claim 108, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

115. The method of claim 108, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

116. A pharmaceutical composition, comprising an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

117. The pharmaceutical composition of claim 116, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

118. The pharmaceutical composition of claim 117, wherein R is nonyl.

119. The pharmaceutical composition of claim 116, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

120. The pharmaceutical composition of claim 119, wherein R is nonyl.

121. The pharmaceutical composition of claim 120, wherein said alkanoyl is butanoyl.

122. The pharmaceutical composition of claim 116, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

123. The pharmaceutical composition of claim 116, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

124. A pharmaceutical composition, comprising an antiviral effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

125. The pharmaceutical composition of claim 124, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

126. The pharmaceutical composition of claim 125, wherein R is nonyl.

127. The pharmaceutical composition of claim 124, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

128. The pharmaceutical composition of claim 127, wherein R is nonyl.

129. The pharmaceutical composition of claim 128, wherein said alkanoyl is butanoyl.

130. The pharmaceutical composition of claim 124, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

131. The pharmaceutical composition of claim 124, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

132. A composition, comprising at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof:

133. The composition of claim 132, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

134. The composition of claim 133, wherein R^A is nonyl.

135. The composition of claim 132, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

136. The composition of claim 135, wherein R^A is nonyl.

137. The composition of claim 136, wherein said alkanoyl is butanoyl.

138. A method as set forth in claim 132 wherein R^A is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀ and branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain.

139. A method as set forth in claim 132 wherein R^A is selected from the group consisting of alkoxyalkyl, arylalkyl, and cycloalkylalkyl.

140. The composition of claim 132, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

141. The composition of claim 132, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;

(−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC);

(−

)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);

(−

)2′

,3′

, dideoxy-3′

-thiacytidine [(−

)-SddC];

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-dexocytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-cytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-cytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-cytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluorothymidine (FddThd);

2′

,3′

-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2′

,3′

-dideoxy-beta-L-5-thiacytidine;

2′

,3′

-dideoxy-beta-L-5-cytidine (beta-L-ddC);

9-(1,3-dihydroxy-2-propoxymethyl)guanine;

2′

-deoxy-3′

-thia-5-fluorocytosine;

3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one (gancyclovir);

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);

3′

-azido-3′

-deoxythymidine (AZT);

3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

9-(2-phosphonyl-methoxyethyl)-2′

,6′

-diaminopurine-2′

,3′

-dideoxyriboside;

9-(2-phosphonylmethoxyethyl)adenine (PMEA);

acyclovir triphosphate (ACVTP);

D-carbocyclic-2′

-deoxyguanosine (CdG);

dideoxy-cytidine;

dideoxy-cytosine (ddC);

dideoxy-guanine (ddG);

dideoxy-inosine (ddI);

E-5-(2-bromovinyl)-2′

-deoxyuridine triphosphate;

fluoro-arabinofuranosyl-iodouracil;

1-(2′

-deoxy-2′

-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);

stavudine;

9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5′

-monophosphate monohydrate (Ara-AMP);

2-deoxy-3′

-thia-5-fluorocytidine;

2′

,3′

-dideoxy-guanine; and

2′

,3′

-dideoxy-guanosine.

142. The composition of claim 132, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof;

and

wherein said nucleoside or nucleotide antiviral compound is (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC).

143. A pharmaceutical composition, comprising:

a first amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof;

wherein R^A is selected from the group consisting of branched or straight chain alkyl having a chain length of C, to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl;

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, an immunomodulator, and immunostimulant, and mixtures thereof; and

a pharmaceutically acceptable carrier, diluent, or excipient,

wherein said first and second amounts of said compounds together comprise an antiviral effective amount of said compounds.

144. The pharmaceutical composition of claim 143, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

145. The pharmaceutical composition of claim 144, wherein R^A is nonyl.

146. The pharmaceutical composition of claim 143, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

147. The pharmaceutical composition of claim 146, wherein R^A is nonyl.

148. The pharmaceutical composition of claim 147, wherein said alkanoyl is butanoyl.

149. A method as set forth in claim 143 wherein R^A is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀ and branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain.

150. A method as set forth in claim 143 wherein R^A is selected from the group consisting of alkoxyalkyl, arylalkyl, and cycloalkylalkyl.

151. The pharmaceutical composition of claim 143, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

152. The pharmaceutical composition of claim 143, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;

(−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC);

(−

)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);

(−

)2′

,3′

, dideoxy-3′

-thiacytidine [(−

)-SddC];

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-dexocytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-cytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-cytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-cytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluorothymidine (FddThd);

2′

,3′

-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2′

,3′

-dideoxy-beta-L-5-thiacytidine;

2′

,3′

-dideoxy-beta-L-5-cytidine (beta-L-ddC);

9-(1,3-dihydroxy-2-propoxymethyl)guanine;

2′

-deoxy-3′

-thia-5-fluorocytosine;

3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one (gancyclovir);

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);

3′

-azido-3′

-deoxythymidine (AZT);

3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

9-(2-phosphonyl-methoxyethyl)-2′

,6′

-diaminopurine-2′

,3′

-dideoxyriboside;

9-(2-phosphonylmethoxyethyl)adenine (PMEA);

acyclovir triphosphate (ACVTP);

D-carbocyclic-2′

-deoxyguanosine (CdG);

dideoxy-cytidine;

dideoxy-cytosine (ddC);

dideoxy-guanine (ddG);

dideoxy-inosine (ddI);

E-5-(2-bromovinyl)-2′

-deoxyuridine triphosphate;

fluoro-arabinofuranosyl-iodouracil;

1-(2′

-deoxy-2′

-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);

stavudine;

9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5′

-monophosphate monohydrate (Ara-AMP);

2-deoxy-3′

-thia-5-fluorocytidine;

2′

,3′

-dideoxy-guanine; and

2′

,3′

-dideoxy-guanosine.

153. The pharmaceutical composition of claim 143, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof;

and

wherein said nucleoside or nucleotide antiviral compound is (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC).

154. A pharmaceutical composition for treating a hepatitis virus infection in a mammal, comprising:

from about 0.1 mg to about 100 mg of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA or a pharmaceutically acceptable salt thereof;

wherein R^A is selected from the group consisting of branched or straight chain alkyl having a chain length of C, to C₂₀, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl;

from about 0.1 mg to about 500 mg of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof; and

a pharmaceutically acceptable carrier, diluent, or excipient.

155. The pharmaceutical composition of claim 154, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

156. The pharmaceutical composition of claim 155, wherein R^A is nonyl.

157. The pharmaceutical composition of claim 154, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

158. The pharmaceutical composition of claim 157, wherein R^A is nonyl.

159. The pharmaceutical composition of claim 158, wherein said alkanoyl is butanoyl.

160. A method as set forth in claim 154 wherein R^A is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀ and branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain.

161. A method as set forth in claim 154 wherein R^A is selected from the group consisting of alkoxyalkyl, arylalkyl, and cycloalkylalkyl.

162. The pharmaceutical composition of claim 154, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

163. The pharmaceutical composition of claim 154, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;

(−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC);

(−

)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);

(−

)2′

,3′

, dideoxy-3′

-thiacytidine [(−

)-SddC];

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-dexocytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluoro-5-methyl-cytidine (FddMeCyt);

2′

,3′

-dideoxy-3′

-chloro-5-methyl-cytidine (ClddMeCyt);

2′

,3′

-dideoxy-3′

-amino-5-methyl-cytidine (AddMeCyt);

2′

,3′

-dideoxy-3′

-fluorothymidine (FddThd);

2′

,3′

-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2′

,3′

-dideoxy-beta-L-5-thiacytidine;

2′

,3′

-dideoxy-beta-L-5-cytidine (beta-L-ddC);

9-(1,3-dihydroxy-2-propoxymethyl)guanine;

2′

-deoxy-3′

-thia-5-fluorocytosine;

3′

-amino-5-methyl-dexocytidine (AddMeCyt);

2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one (gancyclovir);

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);

3′

-azido-3′

-deoxythymidine (AZT);

3′

-chloro-5-methyl-dexocytidine (ClddMeCyt);

9-(2-phosphonyl-methoxyethyl)-2′

,6′

-diaminopurine-2′

,3′

-dideoxyriboside;

9-(2-phosphonylmethoxyethyl)adenine (PMEA);

acyclovir triphosphate (ACVTP);

D-carbocyclic-2′

-deoxyguanosine (CdG);

dideoxy-cytidine;

dideoxy-cytosine (ddC);

dideoxy-guanine (ddG);

dideoxy-inosine (ddI);

E-5-(2-bromovinyl)-2′

-deoxyuridine triphosphate;

fluoro-arabinofuranosyl-iodouracil;

1-(2′

-deoxy-2′

-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);

stavudine;

9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5′

-monophosphate monohydrate (Ara-AMP);

2-deoxy-3′

-thia-5-fluorocytidine;

2′

,3′

-dideoxy-guanine; and

2′

,3′

-dideoxy-guanosine.

164. The pharmaceutical composition of claim 154, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof;

and

wherein said nucleoside or nucleotide antiviral compound is (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC).

165. A pharmaceutical composition for treating a hepatitis virus infection in a human patient, comprising:

from about 0.1 mg to about 100 mg of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof;

from about 0.1 mg to about 500 mg of (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate; and

a pharmaceutically acceptable carrier, diluent, or excipient.

166. A salt of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula IA:

167. The salt of claim 166, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

168. The salt of claim 167, wherein R^A is nonyl.

169. The salt of claim 166, wherein R^A is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

170. The salt of claim 169, wherein R^A is nonyl.

171. The salt of claim 170, wherein said alkanoyl is butanoyl.

172. A method as set forth in claim 166 wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀ and branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain.

173. A method as set forth in claim 166 wherein R is selected from the group consisting of alkoxyalkyl, arylalkyl, and cycloalkylalkyl.

174. The salt of claim 166, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

175. The salt of claim 166, wherein said nucleoside having an acidic moiety is selected from the group consisting of compounds of Formula II, III, IV, V, and VI.

176. The salt of claim 166, wherein said nucleotide is selected from the group consisting of compounds of Formula II, III, IV, V, and VI.

177. The salt of claim 176, wherein said nucleotide is selected from the group consisting of:

(−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate (3TC);

1-(2′

-deoxy-2′

-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

acyclovir triphosphate (ACVTP);

E-5-(2-bromovinyl)-2′

-deoxyuridine triphosphate; and

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5′

-monophosphate monohydrate (Ara-AMP).

178. The salt of claim 166, wherein:

said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate; and

said nucleotide is (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate.

179. A method, comprising reacting N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and (−

)-2′

-deoxy-3′

-thiocytidine-5′

-triphosphate under salt-forming conditions.

180. A salt formed by the method of claim 179.